Dose Escalation of VU319

DRUG2 trials

Sponsors

Vanderbilt University, Vanderbilt University Medical Center

Conditions

Cognitive Impairment

Phase 1

Putative Cognitive Enhancer VU319

CompletedNCT03220295

Vanderbilt UniversityCognitive Impairment

Start: 2017-07-28End: 2019-10-30Updated: 2020-02-06

Multiple Ascending Dose Putative Cognitive Enhancer VU319

WithdrawnNCT04051801

Vanderbilt University Medical CenterCognitive Impairment

Start: 2021-05-25End: 2021-05-25Updated: 2021-05-28

Related Papers

Discovery of VU0467319: an M<sub>1</sub> Positive Allosteric Modulator Candidate That Advanced into Clinical Trials

ACS Chemical Neuroscience2024-12-119 citations